Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Amgen's Pre-Tax Income for the
three
months ended in Sep. 2023 was $1,947 Mil. Amgen's Revenue for the
three
months ended in Sep. 2023 was $6,903 Mil. Therefore, Amgen's pretax margin for the quarter that ended in Sep. 2023 was 28.21%.
The historical rank and industry rank for Amgen's Pretax Margin % or its related term are showing as below:
AMGN'
s Pretax Margin % Range Over the Past 10 Years
Min: 25.79 Med: 34.41 Max: 42
Current: 32.61
AMGN's Pretax Margin % is ranked better than 94.12% of 1038
companies
in the Drug Manufacturers industry
Industry Median: 4.34
vs AMGN: 32.61
Amgen Pretax Margin % Historical Data
The historical data trend for Amgen's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Pretax Margin %
40.19
39.11
31.99
25.79
27.91
Amgen Quarterly Data
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Pretax Margin %
35.96
25.56
56.38
23.10
28.21
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Pretax Margin % Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Amgen's Pretax Margin % falls into.
Amgen Pretax Margin % Calculation
Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.
Amgen's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (NAS:AMGN) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Amgen Pretax Margin % Related Terms
Thank you for viewing the detailed overview of Amgen's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
1.08(0.41%) Volume: 1,978,454 8:08PM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
AMGN has been successfully added to your 